Crohn's Disease Treatment Market to Surpass US$ 10 Billion by 2026

According to the journal of Gastroenterology’s on Inflammatory Bowel Disease (IBD) in 2017, around 1.6 million patient in the U.S were suffering from of IBD, out of which considerable section belongs to Crohn’s disease. Additionally, fast-track drug approval application of FDA pertaining to treatments for Crohn’s disease is also expected to foster the market in the forecast years.

The pipeline drugs offering innovative treatment solutions expecting to receive marketing approvals are anticipated to propel the market growth. For instance, launch of interleukin (IL) inhibitor and anti-integrin therapy for Crohn’s disease, risankizumab, is in the Phase III clinical trials of FDA developed by AbbVie and is expected to complete its trials by January 2022. However, lack of awareness regarding available treatment options is expected to act as hindrance in the market growth.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1237

Moreover, development of new and effective therapy options to cure the symptoms of the disease is also a vital factor contributing to the growth of Crohn’s disease treatment market. For instance, researchers from University of Washington Medicine at the Crohn's & Colitis Congress held in January 2018 presented a study that developed an antibiotic that showed four fold better response on the inflammation of intestine among patients suffering with Crohn’s disease as compared to the existing therapies available in the market.

Additionally, increasing government initiatives for improving health care infrastructure is responsible for the market growth. For instance, The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) is an umbrella organization that represents 34 national patient associations and works for improving the life of patients suffering with irritable bowel syndrome in various countries across Europe.

However, low awareness about the available treatment options among the people of middle and low-income economies as well as biologics going off-patent are expected to hinder the market growth.

In terms of market size, North America dominates the global Crohn’s disease treatment market. This is attributed to rapid development and launch of novel biosimilars and drugs for the treatment of disease by the key players in the market in the region. For instance, in August 2016, the U.S. Food and Drug Administration (FDA) approved two biosimilars Erelzi and Amjevita, manufactured by Amgen for the treatment of inflammatory bowel disease. Moreover, a large population pool of patients suffering from Crohn’s disease in Canada is expected to further support the growth of region in the global market.

Key players in the market are focused on expansion of their presence through launch of new drugs and treatment options worldwide. For instance, in September 2016, Janssen Biotech, Inc, received FDA approval for STELARA for the treatment of moderate to severe Crohn’s disease that have failed responding to the immunomodulators and corticosteroid treatments earlier. Moreover, application of fast-track approval programs by FDA pertaining to IBD treatments is also expected to provide opportunities to market players to capitalize upon and improve significance in the global Crohn’s disease market.

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1237

Key players operating the global Crohn’s disease treatment market include AbbVie Inc., Janssen Biotech, Inc., Allergan Inc., Bayer AG, Bristol-Myers Squibb, Pfizer, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Contact US: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel : +1-206-701-6702 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com